Literature DB >> 15673596

Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?

Cuyue Tang1, Jiunn H Lin, Anthony Y H Lu.   

Abstract

Individual variability in cytochrome P450 (P450) induction comprises an important component contributing to the difficulties in assessing and predicting metabolism-based drug-drug interactions in humans. In this article, we outline the major factors responsible for the individual variability in P450 induction, including variable transporter activity and metabolism of inducers in vivo, genetic variations of P450 genes and their regulatory regions, genetic variations of receptors and regulatory proteins required for induction, and different physiological and environmental elements. With a better understanding of the major determinants in P450 induction and a profile of the phenotypes of these determinants in each individual, it is believed that the individual variability in induction-mediated drug-drug interactions can be adequately evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673596     DOI: 10.1124/dmd.104.003236

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

1.  Metabolism of [D10]phenanthrene to tetraols in smokers for potential lung cancer susceptibility assessment: comparison of oral and inhalation routes of administration.

Authors:  Yan Zhong; Jing Wang; Steven G Carmella; J Bradley Hochalter; Diane Rauch; Andrew Oliver; Joni Jensen; Dorothy K Hatsukami; Pramod Upadhyaya; Cheryl Zimmerman; Stephen S Hecht
Journal:  J Pharmacol Exp Ther       Date:  2011-04-22       Impact factor: 4.030

Review 2.  The role of diet on the clinical pharmacology of oral antineoplastic agents.

Authors:  Antonio Ruggiero; Maria G Cefalo; Paola Coccia; Stefano Mastrangelo; Palma Maurizi; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2011-07-28       Impact factor: 2.953

Review 3.  Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity.

Authors:  Michelle C Sangar; Seema Bansal; Narayan G Avadhani
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

4.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

5.  Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.

Authors:  Mona Darwish; Mary Bond; Ronghua Yang; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

6.  Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin.

Authors:  Liang Yan; Yiting Wang; Jingyang Liu; Yali Nie; Xiao-Bo Zhong; Quancheng Kan; Lirong Zhang
Journal:  Mol Pharmacol       Date:  2017-05-25       Impact factor: 4.436

Review 7.  CYP induction-mediated drug interactions: in vitro assessment and clinical implications.

Authors:  Jiunn H Lin
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

8.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 10.  Clinical pharmacokinetics of antiretroviral drugs in older persons.

Authors:  John C Schoen; Kristine M Erlandson; Peter L Anderson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-03-20       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.